What exactly changed in the OCUL analyst rating on March 02, 2026

William Blair maintained an **Outperform** rating on Ocular Therapeutix, Inc. on March 02, 2026. The firm reiterated its positive stance after study results, but it did not publish a new price target with the note

Does the maintained rating include a new OCUL price target

No. The William Blair note on March 02, 2026 reiterated **Outperform** but did not provide a fresh OCUL price target. Investors should watch for future updates if analysts release new targets

How should investors interpret the OCUL analyst rating relative to stock moves

A maintained Outperform typically signals expected outperformance versus peers. The March 02, 2026 note coincided with a **2.86% ($0.3)** move, showing modest short-term impact but reinforcing medium-term confidence tied to clinical catalysts

What is Meyka AI’s view after this OCUL analyst rating

Meyka AI rates OCUL **B+**, reflecting benchmark and sector checks plus analyst sentiment. The maintained Outperform supports our grade, but we recommend monitoring clinical readouts and future analyst notes

Analyst Ratings

William Blair Maintains Outperform on Ocular Therapeutix, Inc. (OCUL) March 2026

ByHuzaifa Zahoor March 3, 2026March 3, 2026

On March 02, 2026 William Blair maintained an Outperform rating on Ocular Therapeutix, Inc. (OCUL), marking the most notable OCUL analyst rating update today. The firm reiterated its view after recent study results, and StreetInsider reported a 2.86% ($0.3) price move following the announcement. This OCUL analyst rating keeps investor focus on clinical catalysts and near-term stock momentum. Meyka AI rates OCUL with a grade of B+ and tracks how analyst actions like this intersect with earnings, sector trends, and peer benchmarks.